Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Keywords: CANCER ; SURVIVAL ; Germany ; neoplasms ; DIAGNOSIS ; COHORT ; DISEASE ; DISEASES ; MORTALITY ; POPULATION ; RISK ; RISKS ; PATIENT ; RISK-FACTORS ; BREAST ; LYMPHOMA ; NUMBER ; CLINICAL-TRIALS ; risk factors ; case-control studies ; INHIBITORS ; case-control study ; case control studies ; INTERVAL ; DRUGS ; RISK-FACTOR ; PRAVASTATIN ; PROTEIN GERANYLGERANYLATION
    Abstract: Background: Statins, drugs used to treat dyslipidemia, may have anticancer properties. We have evaluated lymphoma risk associated with regular statin use in an international case-control study. Methods: This case-control study included 2,362 cases of incident B- and T-cell lymphoma from Czech Republic, France, Germany, Ireland, Italy, and Spain and 2,206 hospital or population controls. Information on drug use, diagnosis at admission (for hospital controls), and putative risk factors for lymphoma was collected with personal interviews. Hospital controls admitted for diseases possibly entailing use of statins were excluded from the analysis. Results: The odds ratio for regular statin use was 0.61 (95% confidence interval, 0.45-0.84); all major lymphoma subtypes showed similarly decreased risks. Decreased risks were observed in all centers. Duration of statin use was not associated with a greater reduction in the risk of lymphoma. Use of other lipid lowering drugs, such as fibrates, did not significantly modify the risk of lymphoma (odds ratio, 0.75; 95% confidence interval, 0.44-1.27). Conclusion: Statin use was associated with an important reduction in lymphoma risk, adding to the growing evidence of anticancer properties of this group of drugs. These results are reassuring for the increasing number of patients taking statins on a regular basis
    Type of Publication: Journal article published
    PubMed ID: 16702371
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...